If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest: solid tumour
All Signature testsEvery panel compared, side by sideSignature STb33 genes from a blood drawSignature STb O118 genes from blood, including fusionsSignature STb O+523 genes, with TMB, MSI and pharmacogenomicsSignature STt OComprehensive profiling from a tissue blockTest: blood cancer
Signature BML+Myeloid, 600+ genes, with MDS and MPN overlapSignature BLL+Lymphoid, 600+ genes, with Philadelphia-like detectionSignature CustomDesigned around one question when neither family fitsMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillance for solid tumoursClear BloodResidual disease surveillance after blood cancer treatmentProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedJourneysFour composites showing how a decision gets madeCase studiesNine situations and the test that fits eachFAQThe questions we are asked mostCancer Dictionary · Blood and lymphatic
Follicular lymphoma typically grows slowly and often needs no treatment for years. It responds well when treated and tends to return, so it is managed as a long relationship rather than a single course. The two events that change the picture are transformation to an aggressive lymphoma and early progression after first-line treatment.
Also called FL, Indolent B-cell lymphoma.
Start here
Follicular lymphoma is usually incurable and usually compatible with a long life, which inverts the normal logic: the question is rarely how to eradicate it but when, and whether, to treat it at all.
Follicular lymphoma typically grows slowly and often needs no treatment for years. It responds well when treated and tends to return, so it is managed as a long relationship rather than a single course. The two events that change the picture are transformation to an aggressive lymphoma and early progression after first-line treatment.
Before any molecular question
Usually established first: the diagnosis and grade from an adequate biopsy, the stage, the tumour burden, and whether there are indications to treat at all. Being told that no treatment is needed is common here, and is genuinely harder for many people to accept than being treated.
Usually already established
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Grade 1 to 3A
The indolent range. Watchful waiting is appropriate for many patients, sometimes for years.
Grade 3B
Behaves more like an aggressive lymphoma and is generally managed as one. The distinction from 3A is consequential.
Low tumour burden, asymptomatic
Where observation is standard and treating early has not been shown to extend life.
High tumour burden or symptomatic
Where treatment indications are met and the discussion turns to which approach.
Transformed disease
Change into an aggressive lymphoma, usually DLBCL. Confirmed by biopsy, and a different disease from that point on.
Early progression after first-line treatment
A recognised higher-risk group, and a reason to reassess rather than simply repeat.
What is discussed
The BCL2 rearrangement, t(14;18), is characteristic and present in most cases, though it is not by itself diagnostic since it can be found in healthy people. EZH2 mutations define a group of therapeutic interest. CREBBP, KMT2D, TNFRSF14 and ARID1A are commonly altered, reflecting that this is largely a disease of chromatin regulation. TP53 alteration and the acquisition of MYC rearrangement are associated with transformation. CD19 and CD20 expression underpins the immune-based treatment classes.
BCL2 / t(14;18)
Characteristic, but present in healthy people too, so not diagnostic on its own.
EZH2
Mutations define a group with specific therapeutic interest.
CREBBP and KMT2D
Chromatin regulators, commonly altered, reflecting the underlying biology.
TP53
Associated with more aggressive behaviour and with transformation.
MYC
Acquisition is associated with transformation to aggressive lymphoma.
CD19 and CD20
Surface markers underpinning immune-based treatment.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
What is tested, and from what
An adequate biopsy establishes the grade, and the 3A versus 3B distinction matters because it changes the management approach. Repeat biopsy at suspected transformation is the critical test in this disease: transformation is a clinical suspicion that must be confirmed histologically rather than assumed. Comprehensive sequencing is used more in research and in relapsed disease than routinely.
Familial clustering is described and first-degree relatives have a modestly increased risk, but no single high-penetrance gene explains most cases. Germline testing is not part of the routine pathway.
Cancer genetics and hereditary riskctDNA is under study for monitoring and for detecting transformation earlier than clinical change would. In a disease managed over many years with long observation periods, a reliable blood-based marker would be genuinely useful, and this is an active research question rather than settled practice.
More on ctDNA monitoringThe timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
What shapes eligibility
Eligibility is written around prior therapy, time to progression after first-line treatment, and increasingly around specific alterations such as EZH2. Because this disease is managed over many years, the treatment history is long and its detail matters.
| Term | What it means |
|---|---|
| Indolent | Slow growing. Often compatible with a long life, and often not needing immediate treatment. |
| Watchful waiting | Monitoring without treating. An active plan supported by evidence, not a failure to act. |
| Transformation | Change into an aggressive lymphoma. Confirmed by biopsy. |
| Tumour burden | How much disease is present. Part of deciding whether treatment is indicated. |
| t(14;18) | The chromosomal translocation characteristic of follicular lymphoma. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal